menu
    • menu
    [{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Vifor Pharma"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Oncology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Medac","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Fresenius Kabi AG \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Fresenius Kabi"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Oncology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Propofol","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Premier"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Fresenius Kabi AG \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Fresenius Kabi"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Fresenius Kabi"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Fresenius","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Fresenius"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AG \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Fresenius Kabi"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-aacf","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AG \/ Formycon","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Formycon"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Plerixafor","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Fresenius Kabi AG

    Menu

    Fresenius Kabi AG

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tocilizumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fresenius Launches Tyenne®, Its Third Approved Biosimilar in The U.S.

                            Details : Tyenne (tocilizumab) is an interleukin-6 receptor antagonist antibody indicated for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and cytokine release syndrome treatment.

                            Brand Name : Tyenne

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 15, 2024

                            Lead Product(s) : Tocilizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plerixafor

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fresenius Kabi Launches Plerixafor Injection

                            Details : Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.

                            Brand Name : Mozobil-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 09, 2023

                            Lead Product(s) : Plerixafor

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Formycon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fresenius Kabi and Formycon Secure U.S. License Date for Proposed Ustekinumab Biosimilar

                            Details : FYB202 (ustekinumab biosimilar) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin 23 for treatment of immune-mediated disorders.

                            Brand Name : FYB202

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 07, 2023

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Formycon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab-aacf

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fresenius Kabi Launches its Citrate-free Biosimilar Ldacio (adalimumab-aacf) in the United States

                            Details : Idacio (adalimumab-aacf) is a biosimilar product of HUMIRA®, formulated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritisetc. The drug bind specifically to TNF-alpha and block its interaction with the p55 and p7...

                            Brand Name : Idacio

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 03, 2023

                            Lead Product(s) : Adalimumab-aacf

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Mabxience

                            Deal Size : $553.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Fresenius Kabi Completes Majority Stake Acquisition Of mAbxience Holding S.L., Significantly Enhancing Presenc...

                            Details : mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (rituximab), through its in-house biosimilars programs and through its investment in mAbxience, Fresenius expects rapid growth in biopharmaceutical ...

                            Brand Name : Novex

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 01, 2022

                            Lead Product(s) : Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Mabxience

                            Deal Size : $553.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bortezomib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fresenius Kabi Introduces New Generic for the Treatment of Multiple Myeloma

                            Details : Bortezomib, a new generic equivalent to Velcade® in U.S, is available in a 3.5 mg per 10mL single-dose vial presentation for subcutaneous or intravenous use, a treatment option for adult patients with multiple myeloma and mantle cell lymphoma.

                            Brand Name : Bortezomib-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 02, 2022

                            Lead Product(s) : Bortezomib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rituximab,Cyclophosphamide,Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Mabxience

                            Deal Size : $553.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Fresenius Kabi Buys a Majority Stake In mAbxience

                            Details : mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (Rituximab), through its in-house biosimilars programs and through its investment in mAbxience Fresenius expects rapid growth in biopharmaceutical m...

                            Brand Name : Novex

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : Rituximab,Cyclophosphamide,Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Mabxience

                            Deal Size : $553.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icatibant Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fresenius Kabi Launches Icatibant Injection to Treat Acute Attacks of Hereditary Angioedema in Adults

                            Details : Icatibant injection is therapeutically equivalent to Firazyr®, and supplied as a 3 mL prefilled, single-use syringe that is self-administered subcutaneously into the abdominal area.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 01, 2020

                            Lead Product(s) : Icatibant Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Recipient : CSL Vifor

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            VFMCRP and Fresenius Kabi Expand Collaboration in Nephrology in China with Veltassa® Agreement

                            Details : Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chroni...

                            Brand Name : Veltassa

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 19, 2020

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Recipient : CSL Vifor

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Heparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Premier

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ProvideGx® Partners with Fresenius Kabi to Help Stabilize Supply of Heparin

                            Details : Premier with Fresenius Kabi aims at supplying pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpati...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 18, 2020

                            Lead Product(s) : Heparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Premier

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth